Loading stock data…
$1.39-0.01 (-0.71%)
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States.
Enveric Biosciences, Inc. in the Healthcare sector is trading at $1.39 with a market capitalization of $7M. The stock is currently near its 52-week low of $1.17, remaining 35.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.03M↓ | -$1.63M↑ | -$2.19M↓ | -$1.87M↑ | -$2.52M |
| Net Income | -$3.03M↓ | -$1.63M↑ | -$2.19M↓ | -$1.87M↑ | -$2.52M |
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003,...